IN2014DN07509A - - Google Patents

Info

Publication number
IN2014DN07509A
IN2014DN07509A IN7509DEN2014A IN2014DN07509A IN 2014DN07509 A IN2014DN07509 A IN 2014DN07509A IN 7509DEN2014 A IN7509DEN2014 A IN 7509DEN2014A IN 2014DN07509 A IN2014DN07509 A IN 2014DN07509A
Authority
IN
India
Prior art keywords
independently
optionally substituted
therapy
halogen
compounds
Prior art date
Application number
Inventor
Stephen Joseph Shuttleworth
Franck Alexandre Silva
Original Assignee
Karus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karus Therapeutics Ltd filed Critical Karus Therapeutics Ltd
Publication of IN2014DN07509A publication Critical patent/IN2014DN07509A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: R1, R2, R3, R,and R6 are each independently (LQ)mY; R4 is H, halogen, optionally substituted aryl or optionally substituted alkyl; and; each X is independently CR7 or N. The compounds are PI3K inhibitors and therefore have potential utility in therapy.
IN7509DEN2014 2012-03-08 2013-03-08 IN2014DN07509A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1204125.7A GB201204125D0 (en) 2012-03-08 2012-03-08 Compounds
PCT/GB2013/050583 WO2013132270A1 (en) 2012-03-08 2013-03-08 Phosphoinositide 3-kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN07509A true IN2014DN07509A (en) 2015-04-24

Family

ID=46026238

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7509DEN2014 IN2014DN07509A (en) 2012-03-08 2013-03-08

Country Status (6)

Country Link
US (2) US9663487B2 (en)
EP (1) EP2822943B1 (en)
CN (1) CN104254532A (en)
GB (1) GB201204125D0 (en)
IN (1) IN2014DN07509A (en)
WO (1) WO2013132270A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597983A (en) 2009-08-20 2014-05-30 Karus Therapeutics Ltd Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
IN2015DN03235A (en) 2012-11-07 2015-10-02 Karus Therapeutics Ltd
CN104870017B (en) 2012-11-08 2020-08-14 理森制药股份公司 Pharmaceutical composition containing PDE4 inhibitor and PI3 or dual PI 3-gamma kinase inhibitor
PT2994465T (en) 2013-05-10 2018-10-25 Karus Therapeutics Ltd Novel histone deacetylase inhibitors
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
AR117398A1 (en) 2018-03-12 2021-08-04 Abbvie Inc INHIBITORS OF SIGNALING MEDIATED BY TYROSINE KINASE 2

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445742A1 (en) 1963-11-06 1968-12-19 Bayer Ag Process for the preparation of 2-position substituted benzoxazinones
US4017500A (en) 1973-07-16 1977-04-12 Schering Corporation Certain 8-amino-1,7-naphthyridines
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
CN100345830C (en) 2000-04-27 2007-10-31 安斯泰来制药有限公司 Condensed heteroaryl derivatives
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2002002551A1 (en) 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
FR2846657B1 (en) 2002-11-05 2004-12-24 Servier Lab NOVEL PYRIDOPYRIMIDINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2005082887A1 (en) 2004-02-26 2005-09-09 Aska Pharmaceutical Co., Ltd. Pyrimidine derivative
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
MX2007014619A (en) * 2005-05-20 2009-02-13 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase.
EP1979353A2 (en) 2006-01-19 2008-10-15 OSI Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
WO2007122410A1 (en) 2006-04-26 2007-11-01 F.Hoffmann-La Roche Ag Pyrimidine derivatives as pi3k inhibitors
KR101402474B1 (en) 2006-04-26 2014-06-19 제넨테크, 인크. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
CN101605797A (en) 2006-11-13 2009-12-16 伊莱利利公司 The Thienopyrimidinones of treatment inflammatory disease and cancer
CN101663276A (en) * 2007-01-31 2010-03-03 沃泰克斯药物股份有限公司 2-aminopyridine derivatives useful as kinase inhibitors
MX2009008253A (en) 2007-01-31 2009-10-12 Vertex Pharma Kinase inhibitors.
WO2008121257A1 (en) 2007-03-28 2008-10-09 Merck & Co., Inc. Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators
WO2008150827A1 (en) 2007-05-29 2008-12-11 Smithkline Beecham Corporation Naphthyridine, derivatives as p13 kinase inhibitors
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
CA2732087A1 (en) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Substituted naphthyridines and their use as medicaments
CA2742550A1 (en) 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
US8981087B2 (en) 2009-07-29 2015-03-17 Karus Therapeutics Limited Benzo [E] [1,3] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
NZ597983A (en) 2009-08-20 2014-05-30 Karus Therapeutics Ltd Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
US20110207736A1 (en) 2009-12-23 2011-08-25 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
CA2881993C (en) 2011-07-27 2017-05-09 Astrazeneca Ab Substituted 4-methoxy-n3-(pyrimidin-2-yl)benzene-1,3-diamine compounds, and salts thereof
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
RU2015118647A (en) 2012-11-20 2017-01-10 Дженентек, Инк. AMINOPYRIMIDINE COMPOUNDS AS T790M MUTANT EGFR INHIBITORS
PT2994465T (en) 2013-05-10 2018-10-25 Karus Therapeutics Ltd Novel histone deacetylase inhibitors
EP3052494B1 (en) 2013-06-28 2018-12-26 H. Hoffnabb-La Roche Ag Azaindazole compounds as inhibitors of t790m containing egfr mutants
US20150105383A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use

Also Published As

Publication number Publication date
US20150080395A1 (en) 2015-03-19
EP2822943A1 (en) 2015-01-14
WO2013132270A1 (en) 2013-09-12
CN104254532A (en) 2014-12-31
EP2822943B1 (en) 2018-10-03
US10035785B2 (en) 2018-07-31
US20180072699A1 (en) 2018-03-15
US9663487B2 (en) 2017-05-30
GB201204125D0 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
IN2014DN07509A (en)
MX2016006336A (en) Pyrazolopyrimidine compounds.
SA515360469B1 (en) Heterocyclic compounds for inhibiting glutaminase and their methods of use
TN2012000401A1 (en) Heterocyclic compound
NZ705705A (en) Ret inhibitor
PH12014501719A1 (en) Pyridone derivatives
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
MX344025B (en) Protein kinase inhibitors.
UA108926C2 (en) LibreOfficeKINASE PYRROLO[2,3-DEPENDENT INHIBITORS
IN2014MN02598A (en)
MY193277A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
JO3115B1 (en) Pyridazinone Compounds and Their Use as DAAO Inhibitors
RS54526B1 (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
MY172422A (en) Pyrazole compound and pharmaceutical use thereof
GB201209587D0 (en) Therapeutic compounds
PH12015502429A1 (en) Dicarboxylic acid compound
MX2013005819A (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture.
MX2014015345A (en) Pyranopyridone inhibitors of tankyrase.
MX359399B (en) 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS.
CY1117011T1 (en) AZOLI PRODUCERS
MY163185A (en) 2-methoxy-pyridin-4-yl derivatives
MX2015002705A (en) Pyridinone compounds for use in photodynamic therapy.
IN2014CN04922A (en)
MY173812A (en) 2-pyridone compound